Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

"megadose oral methylprednisolone methylprednisolone Multiple Sclerosis" Channels RSS

09:08 EDT 30th July 2014 | BioPortfolio

BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.

Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html

Interested? Contact priority@bioportfolio.com

Showing "megadose oral methylprednisolone methylprednisolone Multiple Sclerosis" Channels 1–25 of 68

Relevant

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the entire immune system, and thus restore immunological bal...

Systemic Sclerosis

Oral Administration

Oral appliances

Oral Contraceptives

Oral treatment

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

Oral and Pharyngeal Disorders

Oral antihyperglycemic drugs

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Multiple cysts

Oral Squamous Cell Carcinoma

Proliferation inducing ligand APRIL

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Primary lateral sclerosis and progressive pseudobulbar palsy

Probably Relevant

Multifetal multiple pregnancy

Multiple screening tests

Multiple System Atrophy

B cell activating factor of the TNF family BAFF

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Multiple Chemical Sensitivity Syndrome

Multiple Endocrine Neoplasia MEN Syndromes

Multiple Endocrine Neoplasia Type 1 MEN 1

Multiple Endocrine Neoplasia Type 2A MEN 2A

Multiple Endocrine Neoplasia Type 2B MEN 2B

Neurotrophic Growth Factors NGF BDNF CNTF

Early clinical trials with classical neurotrophic growth factor proteins such as NGF, BDNF, CNTF have failed for various reasons including safety, efficacy and convenience of administration as well as right definition of the clinical indication. Today quit...


Search BioPortfolio:
Advertisement
Advertisement

Channels Quicklinks